A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Trial Profile

A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs JCAR 015 (Primary)
  • Indications Acute lymphoblastic leukaemia; B-cell leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Jun 2017 Results (n=51) of retrospective analysis focussing on long term survival and reduction of toxicities presented at the 22nd Congress of the European Haematology Association.
    • 25 Jun 2017 Results (n=51) assessing clinical and serum biomarkers associated with sNTX in adult patients with relapsed or refractory B Cell Acute Lymphoblastic Leukemia, presented at the 22nd Congress of the European Haematology Association.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top